Core Viewpoint - Fosun Pharma (01652) experienced a significant stock price increase, rising nearly 74% during trading, with a current increase of 49.28% to HKD 1.03, and a trading volume of HKD 10.37 million [1] Group 1: Product Approvals - The company's wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration of China for the listing application of "Enzalutamide Soft Capsules" [1] - The approved indications include treatment for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) in adult patients and asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) in adult patients who have not received chemotherapy after androgen deprivation therapy (ADT) failure [1] Group 2: Other Product Developments - Fosun Pharma announced that its product Metformin and Ertugliflozin Tablets (I) has been proposed for winning the bid in the recently published results of the 11th batch of national centralized drug procurement in China [1] - The company previously announced in September that the listing application for "Metformin and Ertugliflozin Tablets (I)" has also been approved by the National Medical Products Administration of China [1]
福森药业盘中涨近74% 恩扎卢胺软胶囊获批上市 二甲双胍恩格列净片拟中选国家集采